Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01070017 | Community-based Accompaniment With Supervised Antiretrovirals in Lima, Peru | PHASE3 | COMPLETED | 1,244 | — | — | Feb 1, 2010 | Aug 1, 2014 | Oct 25, 2017 | 1 | Peru |
| Arm | Type | Description |
|---|---|---|
| Intervention: DOT-HAART | EXPERIMENTAL | Intervention group will receive community-based monthly adherence visits, standard care, and DOT-HAART. |
| No DOT-HAART | NO_INTERVENTION | Control group receives community-based monthly adherence visits and standard care, but no DOT-HAART. |
| Name | Type | Description |
|---|---|---|
| DOT-HAART | OTHER | For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration. |
Inclusion Criteria for Patient Cohort: * Age greater than or equal to 18; * Diagnosis if HIV and meeting criteria for HAART; * Lives in poverty; * EITHER: 1) HAART naïve or 2) starting salvage therapy due to virologic failure; * Documentation of baseline CD4 cell count and HIV load; * Residence and...